Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension

Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients

NCT01781052 ·Status: COMPLETED

Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension

NCT00414687 ·Status: COMPLETED ·Phase: PHASE2

Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)

NCT02825160 ·Status: COMPLETED

Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects

NCT00741819 ·Status: COMPLETED ·Phase: PHASE4

Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension

NCT03293407 ·Status: COMPLETED

Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)

NCT00882947 ·Status: COMPLETED

Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension

NCT00709098 ·Status: COMPLETED ·Phase: PHASE3

Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension

NCT01971450 ·Status: COMPLETED

Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension

NCT00453414 ·Status: WITHDRAWN ·Phase: PHASE2

Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)

NCT01437878 ·Status: TERMINATED ·Phase: PHASE2

Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension

NCT01054105 ·Status: COMPLETED

Hypertension Study of Ventavis® Inhalation Therapy in the Treatment of Patients With Pulmonary Arterial Hypertension (VENIS)

NCT01062282 ·Status: COMPLETED

Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis

NCT00109681 ·Status: COMPLETED ·Phase: PHASE2

Ventavis® Registry Protocol

NCT00902603 ·Status: TERMINATED

The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting

NCT00467896 ·Status: TERMINATED ·Phase: PHASE2

Iloprost Power Disc-15 in Pulmonary Arterial Hypertension

NCT00723554 ·Status: TERMINATED ·Phase: PHASE3

Iloprost Power 15 in Pulmonary Arterial Hypertension

NCT00709956 ·Status: COMPLETED ·Phase: PHASE3

Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction

NCT00458042 ·Status: TERMINATED ·Phase: PHASE4

Iloprost-Study: Comparison of Nitric Oxide to Iloprost (Ventavis) for Treatment of Pulmonary Hypertension in Children After Cardiopulmonary Bypass Surgery

NCT00235521 ·Status: COMPLETED ·Phase: NA

Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System

NCT01468545 ·Status: COMPLETED

Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)

NCT02826252 ·Status: COMPLETED

The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension

NCT00302211 ·Status: TERMINATED ·Phase: PHASE3

Comparative PK PD Study in PAH Patients (Fox vs. I-Neb)

NCT02032836 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH

NCT02725372 ·Status: TERMINATED ·Phase: PHASE3

Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)

NCT00694850 ·Status: COMPLETED ·Phase: PHASE2